Olema Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Olema Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Olema Pharmaceuticals Inc recorded a cumulative net loss of $-205 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -35.19%.

However, within the Healthcare sector 513 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3807, from total ROA ranking in the first quarter of 2026 at 4431.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	136.78 %	29.85 %	20.09 %	52.76 %	50.77 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-205	-185	-162	-150	-142
Return On Assets (TTM)	-35.19 %	-41.07 %	-38.64 %	-37.7 %	-38.72 %
OLMA's Total Ranking	# 3807	# 4431	# 3872	# 3920	# 3994
Total Assets (TTM) in million	904	531	540	351	382
Seq. Total Assets Change	70.33 %	-1.69 %	53.63 %	-7.96 %	-6.59 %
Seq. Net Income Change	-	-	-	-	-

OLMA's 5 Years Annual ROA >> Back to OLMA Management Effectiveness >> Compare OLMA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 211
Sector	# 514
Overall	# 3798

Return On Assets Statistics
High	Average	Low
-22.58 %	-39.61 %	-49.24 %
(Dec 31 2021)		(Mar 31 2023)

News about Olema Pharmaceuticals Inc Return on Assets ROA

Olema Oncology Appoints Legal Expert Shawnte M. Mitchell Amid Financial Challenges and Growth Strategy in Biopharmaceutical Sector,

On February 18, 2025, Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer, announced the appointment of Shawnte M. Mitchell, J.D. as its Chief Legal Officer and Corporate Secretary. This strategic appointment comes in the wake of significant challenges faced by the company, including a substantial cumulative net loss of $123 million over the twelve months leading up to the third quarter of 2024. This financial backdrop has resulted in a negative return on assets (ROA) of -48.17%, positioning Olema among a competitive landscape where 571 other companies in the healthcare sector boast higher ROA.Mitchell’s arrival signifies Olema’s dynamic response to the evolving needs of its operational framework. With a storied career as a corporate legal professional, she is expected to provide critical oversight on legal and governance matters, steering the company towards compliance and strategic growth initiatives. Olema s CEO remarked on Mitchell’s extensive experience and dedication to driving organizational value, highlighting her potential to enhance Olema’s mission of pioneering innovative treatments for breast cancer.

Financial Statements
Olema Pharmaceuticals Inc 's Assets	$ 904 million	OLMA's Balance sheet
Olema Pharmaceuticals Inc 's Income	$ -63 million	Quarterly OLMA's Income Statement
OLMA's Income by Division		See OLMA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	18.68 %	63.73 %	28.05 %	-26.87 %	-
Total Assets in million	533	449	275	214	293
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-162	-129	-97	-105	-71
Annual Return On Assets	-30.45 %	-28.81 %	-35.21 %	-48.88 %	-24.25 %

OLMA's 5 Years Annual ROA >> Back to OLMA Management Effectiveness >> Compare OLMA ROA to its Competitors

More Return On Assets Ratios
OLMA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OLMA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OLMA's Competitors
Subscribers only: Roa for Olema Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for OLMA's Customers

You may also want to know
OLMA's Roi	OLMA's Inventory Turnover Ratio	OLMA's Growth Rates	OLMA's Dividend Comparisons
	OLMA's Profitability Ratios	OLMA's Asset Turnover Ratio	OLMA's Dividend Growth
OLMA's Roe	OLMA's Valuation Ratios	OLMA's Financial Strength Ratios	OLMA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T19:42:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.